Amarin (NASDAQ:AMRN) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, September 18th.

A number of other research firms also recently weighed in on AMRN. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. ValuEngine raised Amarin from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Tuesday, June 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $21.75.

Amarin stock traded up $0.34 during mid-day trading on Tuesday, hitting $19.65. 20,482,459 shares of the company’s stock were exchanged, compared to its average volume of 5,771,644. The company has a debt-to-equity ratio of -1.25, a current ratio of 1.43 and a quick ratio of 1.13. The company has a market capitalization of $4.76 billion, a price-to-earnings ratio of -78.60 and a beta of 0.32. Amarin has a 1-year low of $2.35 and a 1-year high of $21.05.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.03). The firm had revenue of $52.64 million during the quarter, compared to the consensus estimate of $54.88 million. The business’s revenue was up 16.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.04) earnings per share. As a group, sell-side analysts anticipate that Amarin will post -0.42 earnings per share for the current year.

In related news, insider Steven B. Ketchum sold 879,241 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $11.10, for a total value of $9,759,575.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Joseph T. Kennedy sold 50,249 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $16.81, for a total transaction of $844,685.69. The disclosure for this sale can be found here. Insiders sold 2,975,800 shares of company stock valued at $33,975,779 in the last quarter. 4.08% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRN. Private Advisor Group LLC grew its holdings in Amarin by 81.8% during the 1st quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 28,929 shares during the period. DRW Securities LLC grew its holdings in Amarin by 45.1% during the 1st quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 25,000 shares during the period. Claraphi Advisory Network LLC grew its holdings in Amarin by 637.3% during the 1st quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 73,738 shares during the period. Northern Trust Corp grew its holdings in Amarin by 20.9% during the 2nd quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 19,590 shares during the period. Finally, TD Asset Management Inc. grew its holdings in Amarin by 54.4% during the 2nd quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock worth $415,000 after acquiring an additional 47,300 shares during the period. 38.27% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.